Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy

被引:18
|
作者
Abuqbeitah, Mohammad [1 ]
Demir, Mustafa [1 ]
Uslu-Besli, Lebriz [1 ]
Yeyin, Nami [1 ]
Sonmezoglu, Kerim [1 ]
机构
[1] Istanbul Univ, Cerrahpasa Fac Med, Dept Nucl Med, Istanbul, Turkey
关键词
Lu-177-DOTATATE; Lu-177-PSMA; Radiation exposure; Dose rate; Blood clearance; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS; RECEPTOR;
D O I
10.1007/s00411-017-0721-6
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The main target of this work is to examine blood clearance and external exposure for Lu-177-DOTATATE compared with new emerging Lu-177-PSMA therapy. Blood clearance and radiation exposure of 31 patients treated with 5.5 +/- 1.1 GBq Lu-177-DOTATATE were compared to those of 23 patients treated with 7.4 GBq Lu-177-PSMA. Dose rates were measured at several distances and time points up to 120 h after treatment. Blood samples were collected conjunctively after infusion. Caregiver's cumulative dose was measured by means of an OSL (optically stimulated luminescence) dosimeter for 4-5 days and medical staff's dose was also estimated using electronic personal dosimeters. Finger dose was determined via ring TLD (Thermoluminescence Dosimeter) for radiopharmacists and nurses. Dose rates due to Lu-177-DOTATATE at a distance of 1 m, 4 h and 6 h after infusion, were 3.0 +/- 2.8 and 2 +/- 1.9 A mu Sv/(h GBq), respectively, while those due to Lu-177-PSMA were 3.1 +/- 0.8 and 2.2 +/- 0.9 A mu Sv/(h GBq). Total effective dose of 17 caregivers was 100-200 A mu Sv for Lu-177-DOTATATE therapy. Mean effective doses to nurses and radiopharmacists were 5 and 4 A mu Sv per patient, respectively, while those for physicists and physicians were 2 A mu Sv per patient. For Lu-177-DOTATATE, effective half-life in blood and early elimination phase were 0.31 +/- 0.13 and 4.5 +/- 1 h, while they were found as 0.4 +/- 0.1 and 5 +/- 1 h, respectively, for Lu-177-PSMA. The first micturition time following Lu-177-DOTATATE infusion was noted after 36 +/- 14 min, while the second and third voiding times were after 74 +/- 9 and 128 +/- 41 min, respectively. It is concluded that blood clearance and radiation exposure for Lu-177-DOTATATE are very similar to those for Lu-177-PSMA, and both treatment modalities are reasonably reliable for outpatient treatment, since the mean dose rate [2.1 A mu Sv/(h GBq)] decreased below the dose rate that allows release of the patient from the hospital (20 A mu Sv/h) after 6 h at 1 m distance.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 50 条
  • [41] EFFICACY OF 177LU-DOTATATE THERAPY IN RECURRENT ANAPLASTIC MENINGIOMA
    Kizilbash, Sani
    Johnson, Derek
    NEURO-ONCOLOGY, 2019, 21 : 140 - 140
  • [42] Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrasekhar
    EJNMMI RESEARCH, 2019, 9 (1)
  • [43] The Interference of Gamma Rays With Bone Mineral Density Measurements in 177Lu-PSMA and DOTATATE Therapy
    Isikci, Nazenin Ipek
    Abuqbeitah, Mohammad
    Demir, Mustafa
    JOURNAL OF CLINICAL DENSITOMETRY, 2022, 25 (02) : 237 - 243
  • [44] Lu-177-DOTATATE Peptide Receptor Radionuclide Therapy
    Abbott, Amanda
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2018, 46 (03) : 245 - 246
  • [45] Optimisation of the Radiation Dosimetry Protocol in 177Lu-PSMA Therapy
    Mink, M.
    Peters, S. M.
    Prive, B. M.
    de Bakker, M.
    Muselaers, C. H.
    Mehra, N.
    Witjes, J. A.
    Gotthardt, M.
    Timmermans, C. W.
    Nagarajah, J.
    Konijnenberg, M. W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S73 - S73
  • [46] Urinary excretion kinetics of 177Lu-PSMA
    de Bakker, M.
    Dominicus, N.
    Meeuwis, A.
    Janssen, M. J. R.
    Konijnenberg, M. W.
    Nagarajah, J.
    Peters, S. M. B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S36 - S36
  • [47] Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C
    Jafari, Esmail
    Ahmadzadehfar, Hojjat
    Bagheri, Dara
    Amini, Abdullatif
    Assadi, Majid
    NUCLEAR MEDICINE COMMUNICATIONS, 2021, 42 (03) : 325 - 331
  • [48] Ambient Dose Equivalent and Occupational Exposure for 177Lu-PSMA-I&T Radionuclide Therapy
    Hu, Z.
    Liu, C.
    Liu, J.
    Yang, Z.
    Qiu, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S735 - S735
  • [49] Patient level dosimetry for radionuclide therapy: proof of concept for patients receiving 177Lu-DOTATATE
    St James, Sara
    Padilla-Morales, Erika
    Bergsland, Emily
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [50] Modeling Early Radiation DNA Damage Occurring During 177Lu-DOTATATE Radionuclide Therapy
    Tamborino, Giulia
    Perrot, Yann
    De Saint-Hubert, Marijke
    Struelens, Lara
    Nonnekens, Julie
    De Jong, Marion
    Konijnenberg, Mark W.
    Villagrasa, Carmen
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (05) : 761 - 769